Marksans Pharma Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Marksans Pharma şirketinin toplam hissedar öz sermayesi ₹20.9B ve toplam borcu ₹2.4B olup, bu da borç-öz sermaye oranını 11.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ₹26.8B ve ₹6.0B dir. Marksans Pharma 'in FAVÖK'ü ₹4.0B faiz karşılama oranı 32.2 dur. Şirketin ₹7.0B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
11.7%
Borç/özkaynak oranı
₹2.44b
Borç
| Faiz karşılama oranı | 32.2x |
| Nakit | ₹7.01b |
| Eşitlik | ₹20.86b |
| Toplam yükümlülükler | ₹5.95b |
| Toplam varlıklar | ₹26.81b |
Son finansal sağlık güncellemeleri
We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02
Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Recent updates
Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Oct 24Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Sep 21Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05
Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: MARKSANS 'nin kısa vadeli varlıkları ( ₹18.6B ) kısa vadeli yükümlülüklerini ( ₹3.9B ) aşıyor.
Uzun Vadeli Yükümlülükler: MARKSANS şirketinin kısa vadeli varlıkları ( ₹18.6B ) uzun vadeli yükümlülüklerini ( ₹2.1B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: MARKSANS şirketinin toplam borcundan daha fazla nakiti var.
Borcun Azaltılması: MARKSANS 'nin borç/öz sermaye oranı son 5 yılda 19.9% seviyesinden 11.7% seviyesine düştü.
Borç Kapsamı: MARKSANS 'nin borcu işletme nakit akışı ( 94.4% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: MARKSANS 'in borcuna ilişkin faiz ödemeleri EBIT ( 32.2 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.